Advertisement
Canada markets close in 4 hours 8 minutes
  • S&P/TSX

    21,803.60
    -70.12 (-0.32%)
     
  • S&P 500

    5,012.02
    -59.61 (-1.18%)
     
  • DOW

    37,862.12
    -598.80 (-1.56%)
     
  • CAD/USD

    0.7301
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    82.42
    -0.39 (-0.47%)
     
  • Bitcoin CAD

    87,476.53
    -1,173.64 (-1.32%)
     
  • CMC Crypto 200

    1,379.67
    -2.90 (-0.21%)
     
  • GOLD FUTURES

    2,343.10
    +4.70 (+0.20%)
     
  • RUSSELL 2000

    1,966.21
    -29.22 (-1.46%)
     
  • 10-Yr Bond

    4.7020
    +0.0500 (+1.07%)
     
  • NASDAQ

    15,455.54
    -257.21 (-1.64%)
     
  • VOLATILITY

    16.78
    +0.81 (+5.07%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     

Valeant’s Xifaxan and Developments for Ortho-Dermatologics

Valeant’s Xifaxan and Developments for Ortho-Dermatologics

In 4Q17, Valeant Pharmaceuticals International’s (VRX) Xifaxan generated revenues of $275 million, compared to $251 million in 4Q16. That was a 10% growth on a YoY (year-over-year) basis and a 4% decline quarter-over-quarter.